WallStreetZenWallStreetZen

NYSEMKT: ARMP
Armata Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARMP

Based on 1 analyst offering 12 month price targets for Armata Pharmaceuticals Inc

Min Forecast
$9.00+83.3%
Avg Forecast
$9.00+83.3%
Max Forecast
$9.00+83.3%

Should I buy or sell ARMP stock?

Based on 1 analyst offering ratings for Armata Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARMP stock forecasts and price targets.

ARMP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-19

1 of 1

Forecast return on equity

Is ARMP forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ARMP forecast to generate an efficient return on assets?

Company
-37.51%
Industry
20.67%
ARMP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARMP earnings per share forecast

What is ARMP's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.49
Avg 2 year Forecast
-$0.84

ARMP revenue forecast

What is ARMP's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$5.6M+33.32%
Avg 2 year Forecast
$0.0-100%
ARMP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARMP revenue growth forecast

How is ARMP forecast to perform vs Biotechnology companies and vs the US market?

Company
33.32%
Industry
9,333.08%
Market
1,364.9%
ARMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARMP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARMP$4.91$9.00+83.30%Buy
ACHV$5.12$12.00+134.38%Buy
CBIO$12.75$25.60+100.78%Strong Buy
HRTX$1.16$4.50+287.93%Buy
SGMO$0.60$8.33+1,293.48%Strong Buy
View Top Biotech Stocks

Armata Pharmaceuticals Stock Forecast FAQ

Is Armata Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: ARMP) stock is to Buy ARMP stock.

Out of 1 analyst, 0 (0%) are recommending ARMP as a Strong Buy, 1 (100%) are recommending ARMP as a Buy, 0 (0%) are recommending ARMP as a Hold, 0 (0%) are recommending ARMP as a Sell, and 0 (0%) are recommending ARMP as a Strong Sell.

If you're new to stock investing, here's how to buy Armata Pharmaceuticals stock.

What is ARMP's earnings growth forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 128.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,855.71%.

Armata Pharmaceuticals's earnings in 2025 is -$25,707,000.On average, 3 Wall Street analysts forecast ARMP's earnings for 2025 to be -$53,953,481, with the lowest ARMP earnings forecast at -$51,837,658, and the highest ARMP earnings forecast at -$55,540,348.

In 2026, ARMP is forecast to generate -$30,302,640 in earnings, with the lowest earnings forecast at -$29,114,301 and the highest earnings forecast at -$31,193,894.

What is ARMP's revenue growth forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual revenue growth rate of 33.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,333.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,364.9%.

Armata Pharmaceuticals's revenue in 2025 is $4,208,000.On average, 3 Wall Street analysts forecast ARMP's revenue for 2025 to be $203,249,414, with the lowest ARMP revenue forecast at $195,278,848, and the highest ARMP revenue forecast at $209,227,338.

In 2026, ARMP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ARMP's forecast return on assets (ROA) for 2025-2026?

(NYSEMKT: ARMP) forecast ROA is -37.51%, which is lower than the forecast US Biotechnology industry average of 20.67%.

What is ARMP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ARMP price target, the average ARMP price target is $9.00, with the highest ARMP stock price forecast at $9.00 and the lowest ARMP stock price forecast at $9.00.

The Wall Street analyst predicted that Armata Pharmaceuticals's share price could reach $9.00 by May 19, 2026. The average Armata Pharmaceuticals stock price prediction forecasts a potential upside of 83.3% from the current ARMP share price of $4.91.

What is ARMP's Earnings Per Share (EPS) forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's current Earnings Per Share (EPS) is -$0.70. On average, analysts forecast that ARMP's EPS will be -$1.49 for 2025, with the lowest EPS forecast at -$1.43, and the highest EPS forecast at -$1.53. In 2026, ARMP's EPS is forecast to hit -$0.84 (min: -$0.80, max: -$0.86).

What is ARMP's forecast return on equity (ROE) for 2025-2026?

(NYSEMKT: ARMP) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.